Not all providers are equally experienced with the insurance side of prescribing GLP-1 medications
February 6, 2025: Lawsuits Against Rybelsus Manufacturer Novo Nordisk Increase 143 new lawsuits were filed related to injuries experienced after taking Rybelsus and other GLP-1 drugs
Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA
This is why many women in this phase respond particularly well
Peptide therapy should only be used under the supervision of a licensed medical provider
Shi G, Zeng L, Shi J, et al